Cosmo N.V. CMOPF
Set alert
At close · Oct 30
- YTD
- -48.72%
- 1 year
- -17.88%
- Open
- 70.41
- Prev close
- 68.20
- Mkt cap
- 1.17B
- Vol
- 128
- Avg vol
- 370
- EPS
- -0.44
- P/E
- 0.00
More statistics
- Low
- 68.20
- High
- 70.41
News
1 week ago seekingalpha.com
Cosmo N.V. (CMOPF) Discusses Positive Phase 2 Results and Differentiation of Rifamycin 1% Gel in Ulcerative Colitis and Proctitis Transcript
Cosmo N.V. (CMOPF) Discusses Positive Phase 2 Results and Differentiation of Rifamycin 1% Gel in Ulcerative Colitis and Proctitis Transcript
3 months ago seekingalpha.com
Cosmo N.V. (CMOPF) Q2 2026 Earnings Call Transcript
Cosmo N.V. (CMOPF) Q2 2026 Earnings Call Transcript
7 months ago seekingalpha.com
Cosmo Pharmaceuticals N.V. (CMOPF) Q4 2025 Earnings Call Transcript
Cosmo Pharmaceuticals N.V. (CMOPF) Q4 2025 Earnings Call Transcript
10 months ago defenseworld.net
Cosmo Pharmaceuticals (OTC:CMOPF) Stock Price Up 1.1% – Here’s What Happened
Cosmo Pharmaceuticals (OTC: CMOPF - Get Free Report)'s stock price was up 1.1% during trading on Friday. The stock traded as high as C$135.00 and last traded at C$135.00. Approximately 558 shares…
11 months ago gurufocus.com
The Hair-Loss Cure That Just Sent This Stock Exploding 24%--Is Big Pharma Paying Attention?
Cosmo Pharmaceuticals (CMOPF) just delivered the kind of data that can shift an entire market narrative. After releasing late-stage results for its experimental